|
Subject demographics at study enrolment |
|||
| Prednisone group (n = 21) |
Placebo group (n = 19) |
||
|
|
|||
| Age, years – median (range) |
5 (2–11) |
6.1 (3–15) |
|
| Gender |
Female |
8 |
12 |
| Male |
13 |
7 |
|
| Ethnicity |
Caucasian |
18 |
18 |
| Other |
3 |
1 |
|
| Days since illness onset – median (range) |
4 (1–7) |
3 (1–7) |
|
| Symptoms at enrollment- number of subjects (%) |
Rash |
21 (100) |
19 (100) |
| Joint |
17 (81) |
18 (95) |
|
| Gastrointestinal |
18 (86) |
11 (58) |
|
| Renal |
4 (19) |
2 (11) |
|
Huber et al. BMC Medicine 2004 2:7 doi:10.1186/1741-7015-2-7 |
|||